Priya Singhal

Executive Vice President and Head of Development, Biogen

Priya Singhal, MD, MPH, is Executive Vice President and Head of Development at Biogen, where she leads the company’s pipeline and has contributed more than a decade of scientific leadership. She has guided over a dozen product approvals and more than 150 development programs, advancing treatments for serious and rare diseases. Before Biogen, Dr. Singhal held senior R&D roles at Zafgen Inc., Vertex Pharmaceuticals, and Millennium Pharmaceuticals. She earned her MPH from the Harvard School of Public Health, her MD in Internal Medicine in Mumbai, India, and is an invited speaker and guest faculty lecturer at Harvard Medical School.

Dear delegates,

In light of the latest developments and as a precautionary measure, the Cyprus Presidency of the Council of the EU 2026 has decided to postpone this week’s Presidency Conference Advancement of Treatments for Rare Diseases, scheduled to take place in Cyprus 5–6 March 2026.

Further information regarding possible re-arrangement and new dates will be communicated in due course.

We apologise for the inconvenience caused by these adjustments and thank you for your understanding.

Yours sincerely,
The Organizing Committee
Conference “Advancement of Treatments for Rare Diseases”
Cyprus Presidency of the Council of the European Union 2026